GSK wins early FDA approval for lung cancer drug Nelkarmi
GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.
How this was made

The 30-second read
Why it matters
The approval reduces regulatory uncertainty and highlights differentiated design goals (treatment resistance, tolerability, and brain metastasis activity), which can shift expectations for GSK’s oncology portfolio trajectory.
Market read
A concrete FDA approval with specific response-rate figures is a direct catalyst for GSK’s oncology valuation narrative.
What to watch
Commercial impact depends on uptake, competitive positioning versus current ALK inhibitor standards, and whether ongoing filings in other markets translate into timely approvals and label expansion.
Background
The FDA approval is described as early relative to the original decision deadline and is tied to ALKOVE-1 Phase I/II results in patients previously treated with ALK inhibitors.
Ticker impact
GSK won early FDA approval for Nelkarmi, citing ALKOVE-1 Phase I/II data and response rates in previously treated ALK-positive lung cancer patients.
Likely upward bias as the market prices in reduced regulatory risk and potential uptake for an ALK-positive lung cancer therapy with activity including brain metastases.
The article reports a specific FDA approval event ahead of the original deadline, supported by trial response metrics and prior Breakthrough Therapy and Orphan Drug designations.
Market effects
Reinforces FDA receptivity to next-generation ALK inhibitors and may support sentiment for oncology pipeline read-throughs among peers targeting ALK-positive NSCLC.
Could modestly lift UK pharma sentiment given GSK is FTSE 100-listed, though the catalyst is FDA-specific.
May increase global investor focus on ALK-positive lung cancer treatment sequencing and brain-metastasis efficacy claims.
Counterpoint
Approval based on Phase I/II data may still leave uncertainty around confirmatory Phase III outcomes, durability, and real-world adoption versus existing ALK inhibitors.
Key entities
- companyGSK
FTSE 100-listed firm receiving early FDA approval for Nelkarmi.
- drugNelkarmi
Next-generation lung cancer drug for ALK-positive disease, approved based on ALKOVE-1 data.
- regulatorFDA
Granted early approval ahead of the original decision deadline.
- clinical_trialALKOVE-1
Phase I/II trial cited for clinically meaningful and durable responses.




